Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [7]
In the citing paper
“In 2003, Abifadel and colleagues identified gain-of-function mutations in the PCSK9 gene causative of familial hypercholesterolemia, an autosomal dominant trait characterized by an elevation in circulating low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease (CHD) risk (2).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [2]
In the citing paper
“Autosomal Dominant Hypercholesterolemia (ADH), due to mutations in the LDLR, APOB or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to high levels of low-density lipoproteins (LDL).”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“ADH is genetically heterogeneous and associated with mutations in the well-known LDLR (low density lipoprotein receptor) (FH, OMIM #606945), APOB (apolipoprotein B-100) (FDB, OMIM # 144010) and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, Abifadel M et al. 2003) genes.”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilisin family of proprotein convertases (PCs) [2], with an established role in the systemic control of blood cholesterol and a lesser-characterized role in neuronal development and apoptosis [3,4].”
From PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling (2012) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Self-citationA proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11041 · Cited by 1,134
A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 175
Self-citationBiosynthesis and Cellular Trafficking of the Convertase SKI-1/S1P
Elagoz, A., Benjannet, S., Mammarbassi, A., Wickham, L., & Seidah, N. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109011200 · Cited by 113
Self-citationHunt, S. C., Hopkins, P. N., Bulka, K., McDermott, M. T., Thorne, T. L., Wardell, B. B., Bowen, B. R., Ballinger, D. G., Skolnick, M. H., & Samuels, M. E. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.4.1089 · Cited by 109
Cited by
Items 501–600 of 1,044
Clinical Genetic Screening in Adult Patients with Kidney Disease
Cocchi, E., Nestor, J. G., & Gharavi, A. G. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.15141219 · Cited by 85
Norata, G. D., Garlaschelli, K., Grigore, L., Raselli, S., Tramontana, S., Meneghetti, F., Artali, R., Noto, D., Cefalu, A. B., Buccianti, G., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.06.023 · Cited by 85
Watkins, W. S., Hernandez, E. J., Wesołowski, S., Bisgrove, B. W., Sunderland, R. T., Lin, E., Lemmon, G., Demarest, B. L., Miller, T. A., Bernstein, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12582-y · Cited by 85
PCSK9 inhibition in the management of familial hypercholesterolemia
Ogura, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.07.002 · Cited by 84
Homer, V. M., Marais, A. D., Charlton, F., Laurie, A. D., Hurndell, N., Scott, R., Mangili, F., Sullivan, D. R., Barter, P. J., Rye, K.-A., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.022 · Cited by 84
Katsuki, S., K. Jha, P., Lupieri, A., Nakano, T., Passos, L. S. A., Rogers, M. A., Becker-Greene, D., Le, T.-D., Decano, J. L., Ho Lee, L., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.320056 · Cited by 76
Xu, W., Zhang, S., Qin, H., & Yao, K. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05957-3 · Cited by 84
Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights
Stein, R., Ferrari, F., & Scolari, F. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1161-5 · Cited by 83
Dual regulation of the LDL receptor—some clarity and new questions
Attie, A. D., & Seidah, N. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.04.006 · Cited by 83
Self-citationSchroeder, C. I., Swedberg, J. E., Withka, J. M., Rosengren, K. J., Akcan, M., Clayton, D., Daly, N. L., Cheneval, O., Borzilleri, K. A., Griffor, M., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.11.014 · Cited by 83
LDL as a Cause of Atherosclerosis
TOMKIN, G. H. (2012) · The Open Atherosclerosis & Thrombosis Journal · doi:10.2174/1876506801205010013 · Cited by 83
Noguchi, T., Katsuda, S., Kawashiri, M., Tada, H., Nohara, A., Inazu, A., Yamagishi, M., Kobayashi, J., & Mabuchi, H. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.11.018 · Cited by 83
Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype–Genotype Relationship
Sánchez-Hernández, R. M., Civeira, F., Stef, M. A., Pérez‐Calahorra, S., Almagro, F., Plana, N., Novoa, F. J., de Aranzubía, P. S., Mosquera, D., Soler, C., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001545 · Cited by 83
Brown, N., Cambruzzi, J., Cox, P. J., Davies, M., Dunbar, J., Plumbley, D., Sellwood, M. A., Sim, A., Williams-Jones, B. I., Zwierzyna, M., et al. (2018) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2017.12.003 · Cited by 83
Familial Hypercholesterolaemia Diagnosis and Management
Alonso, R., de Isla, L. P., Muñiz-Grijalvo, O., Díaz-Díaz, J. L., & Mata, P. (2018) · European Cardiology Review · doi:10.15420/ecr.2018:10:2 · Cited by 83
Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing
Tang, H., Zhao, X., & Jiang, X. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.03.001 · Cited by 83
RNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82
“Autosomal dominant hypercholesterolemia (ADH) is associated with mutations in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene.[215] Patients with ADH usually suffer from coronary heart disease because of the high level of low-density lipoprotein cholesterol.”
BackgroundMethodMaxwell, K. N., & Breslow, J. L. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000162321.31925.a3 · Cited by 82
Bile Acid and Cholesterol Metabolism in Atherosclerotic Cardiovascular Disease and Therapy
Chiang, J. Y. L., Ferrell, J. M., Wu, Y., & Boehme, S. (2020) · Cardiology Plus · doi:10.4103/2470-7511.305419 · Cited by 82
Whole genome sequence analysis of blood lipid levels in >66,000 individuals
Selvaraj, M. S., Li, X., Li, Z., Pampana, A., Zhang, D. Y., Park, J., Aslibekyan, S., Bis, J. C., Brody, J. A., Cade, B. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33510-7 · Cited by 69
Hazrati, A., Malekpour, K., Soudi, S., & Hashemi, S. M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113943 · Cited by 82
Plasma PCSK9 levels correlate with cholesterol in men but not in women.
Mayne, J., Raymond, A., Chaplin, A., Cousins, M., Kaefer, N., Gyamera-Acheampong, C., Seidah, N. G., Mbikay, M., Chrétien, M., & Ooi, T. C. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.029 · Cited by 81
Self-citationRoss, S. A., Anand, S. S., Joseph, P. G., & Paré, G. (2012) · JRSM Cardiovascular Disease · doi:10.1258/cvd.2012.012001 · Cited by 81
Macchi, C., Banach, M., Corsini, A., Sirtori, C., Ferri, N., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319831500 · Cited by 75
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Luquero, A., Badimon, L., & Borrell-Pages, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.639727 · Cited by 73
Xie, J., Wang, W., Yang, T., Zhang, Q., Zhang, Z., Zhu, X., Li, N., Zhi, L., Ma, X., Zhang, S., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02822-8 · Cited by 80
Evans, D., & Beil, F. U. (2006) · BMC Medical Genetics · doi:10.1186/1471-2350-7-66 · Cited by 74
Characterization of novel mutations in the catalytic domain of the PCSK9 gene
Cameron, J., Holla, Ø. L., Laerdahl, J. K., Kulseth, M. A., Ranheim, T., Rognes, T., Berge, K. E., & Leren, T. P. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01915.x · Cited by 66
PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
Baragetti, A., Balzarotti, G., Grigore, L., Pellegatta, F., Guerrini, U., Pisano, G., Fracanzani, A. L., Fargion, S., Norata, G. D., & Catapano, A. L. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317724342 · Cited by 79
Luna Saavedra, Y. G., Day, R., & Seidah, N. G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394023 · Cited by 69
Self-citationFenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
Troutt, J. S., Alborn, W. E., Cao, G., & Konrad, R. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m000620 · Cited by 71
Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
Luo, Y., Warren, L., Xia, D., Jensen, H., Sand, T., Petras, S., Qin, W., Miller, K. S., & Hawkins, J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800542-jlr200 · Cited by 71
Guo, Y., Tang, Z., Yan, B., Yin, H., Tai, S., Peng, J., Cui, Y., Gui, Y., Belke, D. D., Zhou, S., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316902 · Cited by 78
Chmara, M., Wasąg, B., Żuk, M., Kubalska, J., Węgrzyn, A., Bednarska‐Makaruk, M., Pronicka, E., Wehr, H., Defesche, J. C., Rynkiewicz, A., et al. (2010) · Journal of Applied Genetics · doi:10.1007/bf03195716 · Cited by 78
Isolation and characterization of the circulating truncated form of PCSK9
Han, B., Eacho, P. I., Knierman, M. D., Troutt, J. S., Konrad, R. J., Yu, X., & Schroeder, K. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m049346 · Cited by 69
New Therapeutic Approaches to the Treatment of Dyslipidemia
Rader, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.005 · Cited by 78
Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery
Zhou, K., Pedersen, H., Dawed, A. Y., & Pearson, E. R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.51 · Cited by 78
Yue, P., Averna, M., Lin, X., & Schonfeld, G. (2006) · Human Mutation · doi:10.1002/humu.20316 · Cited by 72
Abboud, S., Karhunen, P. J., Lütjohann, D., Goebeler, S., Luoto, T., Friedrichs, S., Lehtimaki, T., Pandolfo, M., & Laaksonen, R. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001043 · Cited by 77
“Mutations in this gene have been associated with both hypocholesterolemia and hypercholesterolemia through ‘‘loss-offunction’’ [8] [19] [7] and ‘‘gain-of-function’’ [5] [20] [21] [12], respectively.”
Role of PCSK9 beyond liver involvement
Cariou, B., Si-Tayeb, K., & Le May, C. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000180 · Cited by 77
Li, C., Lin, L., Zhang, W., Zhou, L., Wang, H., Luo, X., Luo, H., Cai, Y., & Zeng, C. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.001937 · Cited by 77
Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia
Burnett, J., Bell, Hooper, & Watts (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s28581 · Cited by 64
Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes
Gan, E. S., Tan, H. C., Le, D. H. T., Huynh, T. T., Wills, B., Seidah, N. G., Ooi, E. E., & Yacoub, S. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137536 · Cited by 70
Self-citationErrata. PCSK9 function and physiology
Peterson, A. S., Fong, L. G., & Young, S. G. (2008) · Journal of Lipid Research · doi:10.1194/jlr.cx00001-jlr200 · Cited by 66
Expanding biology of PCSK9: roles in atherosclerosis and beyond
Seidah, N. G., & Garçon, D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01057-z · Cited by 76
Self-citationThe genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations
Fernando Civeira, F. (2010) · The Application of Clinical Genetics · doi:10.2147/tacg.s8285 · Cited by 76
PCSK9: A novel inflammation modulator in atherosclerosis?
Tang, Z., Li, T., Peng, J., Zheng, J., Li, T., Liu, L., Jiang, Z., & Zheng, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27254 · Cited by 73
Xu, X., Cui, Y., Cao, L., Zhang, Y., Yin, Y., & Hu, X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4218 · Cited by 66
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors
Preiss, D., Tobert, J. A., Hovingh, G. K., & Reith, C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.072 · Cited by 75
Humphries, S. E., Cranston, T., Allen, M., Middleton-Price, H. R., Fernandez, M. C., Senior, V., Hawe, E., Iversen, A., Wray, R., Crook, M. A., et al. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0019-z · Cited by 75
Hooper, A. J., Tang, X. L., & Burnett, J. R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2369747 · Cited by 75
PCSK9: Regulation and Target for Drug Development for Dyslipidemia
Burke, A. C., Dron, J. S., Hegele, R. A., & Huff, M. W. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104944 · Cited by 74
Cesaro, A., Bianconi, V., Gragnano, F., Moscarella, E., Fimiani, F., Monda, E., Scudiero, O., Limongelli, G., Pirro, M., & Calabrò, P. (2020) · BioFactors · doi:10.1002/biof.1619 · Cited by 74
Yamamoto, T., Harada-Shiba, M., Nakatani, M., Wada, S., Yasuhara, H., Narukawa, K., Sasaki, K., Shibata, M.-A., Torigoe, H., Yamaoka, T., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.16 · Cited by 69
Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels
Chernogubova, E., Strawbridge, R., Mahdessian, H., Mälarstig, A., Krapivner, S., Gigante, B., Hellénius, M.-L., de Faire, U., Franco-Cereceda, A., Syvänen, A.-C., et al. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.240549 · Cited by 64
Familial Dyslipidaemias: An Overview of Genetics, Pathophysiology and Management
Hachem, S. B., & Mooradian, A. D. (2006) · Drugs · doi:10.2165/00003495-200666150-00005 · Cited by 74
Konrad, R. J., Troutt, J. S., & Cao, G. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-38 · Cited by 71
Small Molecule Inhibitors of the PCSK9·LDLR Interaction
Taechalertpaisarn, J., Zhao, B., Liang, X., & Burgess, K. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b09360 · Cited by 68
Roth, E. M., & McKenney, J. M. (2015) · Future Cardiology · doi:10.2217/fca.14.82 · Cited by 70
The use of new CRISPR tools in cardiovascular research and medicine
Nishiga, M., Liu, C., Qi, L. S., & Wu, J. C. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00669-3 · Cited by 73
Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists
Zhang, Y., Ultsch, M. H., Skelton, N. J., Burdick, D. J., Beresini, M. H., Li, W., Kong-Beltran, M., Peterson, A. S., Quinn, J. G., Chiu, C., et al. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3453 · Cited by 73
Genetic-Driven Druggable Target Identification and Validation
Floris, M., Olla, S., Schlessinger, D., & Cucca, F. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.04.004 · Cited by 64
“Cholesterol-Years” for ASCVD Risk Prediction and Treatment
Shapiro, M. D., & Bhatt, D. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.004 · Cited by 73
Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants
Dron, J. S., & Hegele, R. A. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000386 · Cited by 72
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Lorenzatti, A. J., & Toth, P. P. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.06 · Cited by 72
Lee, C. J., Lee, Y.-H., Park, S. W., Kim, K. J., Park, S., Youn, J.-C., Lee, S.-H., Kang, S.-M., & Jang, Y. (2013) · Metabolism · doi:10.1016/j.metabol.2013.01.005 · Cited by 65
Lopez, D. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.01.003 · Cited by 72
Shende, V. R., Wu, M., Singh, A. B., Dong, B., Kan, C. F. K., & Liu, J. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m052969 · Cited by 62
Burkart, K. M., Manichaikul, A. W., Wilk, J. B., Ahmed, F. S., Burke, G. L., Enright, P., Hansel, N. N., Haynes, D., Heckbert, S. R., Hoffman, E. A., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00147612 · Cited by 73
Kawakami, R., Nozato, Y., Nakagami, H., Ikeda, Y., Shimamura, M., Yoshida, S., Sun, J., Kawano, T., Takami, Y., Noma, T., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191895 · Cited by 67
Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells
Fasano, T., Sun, X.-M., Patel, D., & Soutar, A. K. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.10.027 · Cited by 72
Molecular genetics of atherosclerosis
Roy, H., Bhardwaj, S., & Ylä‐Herttuala, S. (2009) · Human Genetics · doi:10.1007/s00439-009-0654-5 · Cited by 72
Familial hypercholesterolemia: current treatment and advances in management
Huijgen, R., Vissers, M. N., Defesche, J. C., Lansberg, P. J., Kastelein, J. J., & Hutten, B. A. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.4.567 · Cited by 71
The genetic basis for adult onset glaucoma: Recent advances and future directions
Wang, Z., Wiggs, J. L., Aung, T., Khawaja, A. P., & Khor, C. C. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101066 · Cited by 71
Polisecki, E. Y., Peter, I., Robertson, M., McMahon, A. D., Ford, I., Packard, C. J., Shepherd, J., Jukema, J. W., Blauw, G. J., Westendorp, R. G. J., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.12.005 · Cited by 71
Chan, D. C., Lambert, G., Barrett, P. H. R., Rye, K.-A., Ooi, E. M. M., & Watts, G. F. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.128645 · Cited by 62
Genetic Insights for Drug Development in NAFLD
Eslam, M., & George, J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.05.002 · Cited by 69
Recent advances on nanoparticle-based therapies for cardiovascular diseases
Soumya, R. S., & Raghu, K. G. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.02.009 · Cited by 70
Updated Understanding of the Crosstalk Between Glucose/Insulin and Cholesterol Metabolism
Xiao, X., Luo, Y., & Peng, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.879355 · Cited by 70
LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives
Al-Allaf, F. A., Coutelle, C., Waddington, S. N., David, A. L., Harbottle, R. P., & Themis, M. (2010) · International Archives of Medicine · doi:10.1186/1755-7682-3-36 · Cited by 70
Ferri, N., Corsini, A., Macchi, C., Magni, P., & Ruscica, M. (2015) · Translational research · doi:10.1016/j.trsl.2015.10.004 · Cited by 70
PCSK9 in chronic kidney disease
Pavlakou, P., Liberopoulos, E. N., Dounousi, E. C., & Elisaf, M. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1505-2 · Cited by 70
Pećin, I., Hartgers, M. L., Hovingh, G. K., Dent, R. E., & Reiner, Ž. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317717346 · Cited by 70
Nishikido, T., & Ray, K. K. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00199 · Cited by 62
Holla, Ø. L., Cameron, J., Berge, K. E., Ranheim, T., & Leren, T. P. (2007) · BMC Cell Biology · doi:10.1186/1471-2121-8-9 · Cited by 62
C-Reactive Protein Signaling Pathways in Tumor Progression
Kim, E., Kim, S. Y., & Moon, A. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2023.132 · Cited by 69
New Drugs for Treating Dyslipidemia: Beyond Statins
Ahn, C. H., & Choi, S. H. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.2.87 · Cited by 69
Effects of the Prosegment and pH on the Activity of PCSK9
Benjannet, S., Luna Saavedra, Y. G., Hamelin, J., Asselin, M.-C., Essalmani, R., Pasquato, A., Lemaire, P., Duke, G., Miao, B., Duclos, F., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.154815 · Cited by 62
Self-citationGenetic diagnosis of familial hypercholesterolaemia by targeted next‐generation sequencing
Maglio, C., Mancina, R. M., Motta, B. M., Stef, M. A., Pirazzi, C., Palacios, L., Askaryar, N., Borén, J., Wiklund, O., & Romeo, S. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12263 · Cited by 69
Vlachopoulos, C. V., Terentes-Printzios, D. G., Georgiopoulos, G. A., Skoumas, I., Koutagiar, I. P., Ioakeimidis, N., Stefanadis, C., & Tousoulis, D. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.922 · Cited by 69
Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers
Blacklow, S. C. (2007) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2007.08.017 · Cited by 68
“In 2003, a new molecular culprit for FH was identified: a proprotein convertase of the subtilisin/kexin family called PCSK9 [4].”
BackgroundDelivery of low-density lipoprotein from endocytic carriers to mitochondria supports steroidogenesis
Zhou, Y., Wei, J. N., Deng, G., Hu, A., Sun, P.-Y., Zhao, X., Song, B., & Luo, J. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01160-6 · Cited by 68
Genetic Susceptibility to Atherosclerosis
Kovacic, S., & Bakran, M. (2012) · Stroke Research and Treatment · doi:10.1155/2012/362941 · Cited by 68
Sjouke, B., Hovingh, G. K., Kastelein, J. J. P., & Stefanutti, C. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000179 · Cited by 68
Mechanism of action of anti-hypercholesterolemia drugs and their resistance
Tiwari, V., & Khokhar, M. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.048 · Cited by 68
Chan, D. C., Pang, J., McQuillan, B., Hung, J., Beilby, J. P., Barrett, P. H. R., & Watts, G. F. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.10.017 · Cited by 68
The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
Seidah, N. G. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2017.2 · Cited by 51
Self-citationStatins and Their Effect on PCSK9—Impact and Clinical Relevance
Taylor, B. A., & Thompson, P. D. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0604-3 · Cited by 68
Epigenetics: a link between addiction and social environment
Ajonijebu, D. C., Abboussi, O., Russell, V. A., Mabandla, M. V., & Daniels, W. M. U. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2493-1 · Cited by 68
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021) · Biomedicines · doi:10.3390/biomedicines9070793 · Cited by 67
Metadata
- Authors
- Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., & Boileau, C.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Genoscope (FR)
- Montreal Clinical Research Institute (CA)
- Pitié-Salpêtrière Hospital (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Hôpital Claude Huriez (FR)
- Hospices Civils de Lyon (FR)
- ORCID
- Venue
- Nature Genetics
- Published
- 2003-05-05
- Volume
- 34
- Issue
- 2
- Pages
- 154-156
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2040612932
- Semantic Scholar
- 80bf33c74bfe780bcc1968f318b09647e59f0afe
- Cited by
- 2,985
- References
- 6
- Citations by year
- 2026: 88 · 2025: 115 · 2024: 154 · 2023: 175 · 2022: 163 · 2021: 207 · 2020: 182 · 2019: 173 · 2018: 214 · 2017: 232 · 2016: 214 · 2015: 200 · 2014: 162 · 2013: 131 · 2012: 101
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut National de la Santé et de la Recherche Médicale
- Fondation de France
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PCSK9, autosomal dominant hypercholesterolemia, LDL receptor, apolipoprotein B, LDL cholesterol, genetic mutations, cholesterol homeostasis, subtilases, coronary heart disease risk
- MeSH terms
- Proprotein Convertase 9, Chromosomes, Human, Pair 1, Female, Genes, Dominant, Humans, Hyperlipoproteinemia Type II, Genetic Linkage, Liver, Male, Mutation, Pedigree, Serine Endopeptidases, Amino Acid Substitution, Proprotein Convertases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.